Supernus Pharmaceuticals SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

4Nov. 2, 2026, 4:14 p.m. ETView on SEC.gov
4Nov. 2, 2026, 4:18 p.m. ETView on SEC.gov
4Nov. 2, 2026, 4:15 p.m. ETView on SEC.gov
4Nov. 2, 2026, 4:11 p.m. ETView on SEC.gov
4Nov. 2, 2026, 4:20 p.m. ETView on SEC.gov
4Nov. 2, 2026, 4:17 p.m. ETView on SEC.gov
8-KNov. 2, 2026, 10:50 a.m. ETView on SEC.gov
Delisting notice / failure to meet listing standard
AI summary, unreviewedSupernus Pharmaceuticals, Inc. Stock to Be Delisted From Nasdaq Following Completion of Merger on November 2, 2026
8-KNov. 2, 2026, 9:28 a.m. ETView on SEC.gov
Entry into a material definitive agreement · Completion of acquisition or disposition of assets · Creation of a direct financial obligation · Material modification of security holders' rights · Change in control · Amendments to articles or bylaws; fiscal year change · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedSupernus completes reverse merger with Indivior, issuing 1.5401 Indivior shares per Supernus share and funding a $1.0 billion Indivior special dividend with a $650 million Citibank term loan
10-QOct. 29, 2026, 4:12 p.m. ETView on SEC.gov
8-KOct. 29, 2026, 4:08 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedSupernus Q3 2026 Revenue Rises 18% to Record $226.8 Million, Beats $217.6 Million Consensus; Diluted EPS of $0.35 Misses $0.49 Estimate; FY2026 Guidance Raised, Indivior Merger Closing November 2
8-KOct. 26, 2026, 4:41 p.m. ETView on SEC.gov
Termination of a material definitive agreement · Financial statements and exhibits
AI summary, unreviewedSupernus Pharmaceuticals Terminates Uncommitted $ UBS Credit Line Ahead of Indivior Combination
8-KOct. 21, 2026, 9:07 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
AI summary, unreviewedSupernus Pharmaceuticals Recognized for Seven-Year ONAPGO Orphan-Drug Exclusivity; Second-Supplier sNDA Submitted, Approval Expected Mid-2027
8-KOct. 19, 2026, 4:51 p.m. ETView on SEC.gov
Results of operations and financial condition
AI summary, unreviewedSupernus Pharmaceuticals (SUPN) to report Q3 2026 results after market close on October 29, 2026
8-KOct. 15, 2026, 4:10 p.m. ETView on SEC.gov
Submission of matters to a vote of security holders · Financial statements and exhibits
425Oct. 6, 2026, 7:16 a.m. ETView on SEC.gov
DEFM14ASept. 11, 2026View on SEC.gov
4Aug. 14, 2026, 5:11 p.m. ETView on SEC.gov
4Aug. 14, 2026, 5:10 p.m. ETView on SEC.gov
4Aug. 14, 2026, 5:12 p.m. ETView on SEC.gov
4Aug. 14, 2026, 5:11 p.m. ETView on SEC.gov
4Aug. 14, 2026, 5:09 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 6, 2026, 6:48 p.m. ETView on SEC.gov
425Aug. 3, 2026, 7:04 p.m. ETView on SEC.gov
10-QAug. 3, 2026, 6:56 a.m. ETView on SEC.gov
8-KAug. 3, 2026, 6:46 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
425Aug. 3, 2026, 5:25 p.m. ETView on SEC.gov
425Aug. 3, 2026, 5:04 p.m. ETView on SEC.gov
8-KAug. 3, 2026, 5 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
425Aug. 3, 2026, 8:35 a.m. ETView on SEC.gov
8-KAug. 3, 2026, 8:34 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits